Tag: psoriasis

1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in the sonelokimab groups than in the placebo group. 2. No dose-response associations with toxicity were apparent for the sonelokimab groups. Evidence Rating Level: 1 (Excellent)  Study Rundown: Sonelokimab is a novel trivalent...
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of PASI90 and IGA response. 2. The safety profile of Bimekizumab was overall mild and similar to current treatment option ustekinumab Evidence Rating Level: 1 (Excellent) Study Rundown: Plaque psoriasis is a chronic inflammatory skin...
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of PASI90 and IGA response. 2. The safety profile of Bimekizumab was overall mild and similar to current treatment option ustekinumab Evidence Rating Level: 1 (Excellent) Study Rundown: Plaque psoriasis is a chronic...
1. 91% of patients receiving bimekizumab 320 mg every 4 weeks achieved ≥ 90% improvement from baseline in the Psoriasis Area Severity Index (PASI90) compared to 1% receiving placebo. 2. After achieving PASI90 at week 16, bimekizumab response was maintained through week 56 in both dosing schedules (every 4 weeks...
1. A significantly greater percentage of both roflumilast groups had clear or nearly clear skin compared to the control group after 6 weeks of treatment. 2. A numerically higher number of patients in the higher-dose group achieved the primary outcome, but no statistically significant difference was detected between the treatment...
1. A significantly greater percentage of both roflumilast groups had clear or nearly clear skin compared to the control group after 6 weeks of treatment. 2. A numerically higher number of patients in the higher-dose group achieved the primary outcome, but no statistically significant difference was detected between the treatment...
1. Treatment with biologics in pediatric patients with moderate to severe psoriasis was significantly associated with greater reduction in psoriasis severity than methotrexate, though methotrexate remains an effective treatment for the condition. Evidence Rating: 2 (Good) Psoriasis is a highly debilitating chronic inflammatory skin disorder that affects up to 1.37% of children,...
1. Treatment with biologics in pediatric patients with moderate to severe psoriasis was significantly associated with greater reduction in psoriasis severity than methotrexate, though methotrexate remains an effective treatment for the condition. Evidence Rating: 2 (Good) Psoriasis is a highly debilitating chronic inflammatory skin disorder that affects up to 1.37% of...
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial 1. Study findings suggest that early administration of intravenous dexamethasone during acute respiratory distress syndrome may decrease duration of mechanical ventilation and mortality rates. Evidence Level: 1 (Excellent) Acute respiratory distress syndrome (ARDS), characterized by acute hypoxemic respiratory failure...